Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. AbbVie Inc.
  6. Summary
    ABBV   US00287Y1091

ABBVIE INC.

(ABBV)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
01/10/2022 01/11/2022 01/12/2022 01/13/2022 01/14/2022 Date
136.39(c) 136.97(c) 137.29(c) 133.52(c) 135.87(c) Last
9 794 424 7 159 363 6 589 301 8 386 373 10 484 542 Volume
+1.12% +0.43% +0.23% -2.75% +1.76% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 56 220 M - -
Net income 2021 11 140 M - -
Net Debt 2021 63 349 M - -
P/E ratio 2021 21,8x
Yield 2021 3,86%
Sales 2022 59 677 M - -
Net income 2022 15 739 M - -
Net Debt 2022 50 526 M - -
P/E ratio 2022 14,6x
Yield 2022 4,16%
Capitalization 240 B 240 B -
EV / Sales 2021 5,40x
EV / Sales 2022 4,87x
Nbr of Employees 50 000
Free-Float 98,0%
More Financials
Company
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohnâ'Ts disease, thyroid disease, Parkinsonâ'Ts disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.1%), Japan (2.6%),... 
Sector
Pharmaceuticals
Calendar
02/02Earnings Release
More about the company
Ratings of AbbVie Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about ABBVIE INC.
01/14U.S. FDA approves drugs from AbbVie, Pfizer to treat eczema
RE
01/14FDA approves expanded use of AbbVie's arthritis drug to treat eczema
RE
01/14AbbVie Gets FDA Approval for Rinvoq for Ages 12 and Older
DJ
01/14AbbVie Says FDA Approves Rinvoq to Treat Atopic Dermatitis
MT
01/14U.S. FDA Approves RINVOQ® (upadacitinib) to Treat Adults and Children 12 Years and Olde..
PR
01/14U.S. FDA Approves RINVOQ® (upadacitinib) to Treat Adults and Children 12 Years and Olde..
CI
01/13Redburn Initiates AbbVie With Buy Rating
MT
01/13Today on Wall Street: Time for a new chapter?
01/13ANALYST RECOMMENDATIONS : AbbVie, Asos, Block, Dow, Metlife...
01/13ABBVIE INC. : Ex-dividend day for
FA
01/12BMO Capital Adjusts AbbVie's Price Target to $153 from $134, Keeps Outperform Rating
MT
01/11AbbVie Reiterates Revenue Guidance of More than $15 Billion in Sales for Rinvoq, Skyriz..
MT
01/11AbbVie Confirms Guidance of Greater Than $15 Billion in Combined Risk-Adjusted Sales fo..
PR
01/10Regenxbio Launches Second Trial of Subretinal Delivery Therapy for Wet Age-Related Macu..
MT
01/10Frontier Medicines Announces Advancement of First Program Under Global Partnership with..
CI
More news
News in other languages on ABBVIE INC.
01/14AbbVie déclare que la FDA approuve Rinvoq pour traiter la dermatite atopique
01/14La FDA américaine approuve RINVOQ® (upadacitinib) pour le traitement des adultes et des..
01/13BOLSA DE MADRID : ¿Preparado para el nuevo mundo?
01/13Prêt pour le monde d'après ?
01/13AVIS D'ANALYSTES DU JOUR : Stellantis, Vinci, STMicroelectronics, Soitec, ABB, Asos, Nokia..
More news
Analyst Recommendations on ABBVIE INC.
More recommendations
Chart ABBVIE INC.
Duration : Period :
AbbVie Inc. Technical Analysis Chart | ABBV | US00287Y1091 | MarketScreener
Technical analysis trends ABBVIE INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 24
Last Close Price 135,87 $
Average target price 138,52 $
Spread / Average Target 1,95%
EPS Revisions
Managers and Directors
Richard A. Gonzalez Chairman & Chief Executive Officer
Michael E. Severino Vice Chairman-Management Board & President
Robert A. Michael CFO, Vice Chairman-Finance & Commercial Operations
Thomas J. Hudson Chief Scientific Officer, Senior VP-R&D
Azita Saleki-Gerhardt Executive Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ABBVIE INC.0.35%240 202
JOHNSON & JOHNSON-1.89%441 855
ROCHE HOLDING AG-3.72%323 901
PFIZER, INC.-6.94%308 427
ELI LILLY AND COMPANY-11.62%221 317
NOVO NORDISK A/S-15.01%218 444